Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talizumab

Next Previous
X
Search
Drug Profile

Talizumab

Alternative Names: Anti-IgE monoclonal antibody Hu 901; HU 901; TNX 901

Latest Information Update: 14 Mar 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanox
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Peanut hypersensitivity

Most Recent Events

  • 26 Feb 2004 Genentech, Novartis and Tanox, Inc., have settled all litigation among themselves for the development and commercialisation of certain anti-IgE antibodies including Omalizumab and TNX 901
  • 26 Feb 2004 Suspended - Phase-II for Peanut allergy in USA (unspecified route)
  • 12 Mar 2003 Data from the 60th Anniversary Meeting of the American Academy of Allergy and Asthma and Immunology (AAAAI-2003) have been added to the Immunological Disorders therapeutic trials section ,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top